Ladostigil

Ladostigil
(IUPAC) ime
	[(3R)-3-(prop-2-inilamino)indan-5-il]-N-propilkarbamat
Klinički podaci
Identifikatori
CAS broj	209349-27-4
ATC kod	nije dodeljen
PubChem	208907
ChemSpider	181005
UNII	SW3H1USR4Q
Hemijski podaci
Formula	C16H20N2O2
Mol. masa	272,34 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3 ; Key: LHXOCOHMBFOVJS-UHFFFAOYSA-N
Sinonimi	[N-propargil-(3R)-aminoindan-5il]-N-propilkarbamat
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Nije kontrolisan
Način primene	Oralno

Ladostigil (TV-3,326) je neuroprotektivni agens koji se istražuje za moguću primenu u lečenju neurodegenerativnih poremećaja poput Alchajmerove bolesti, demencije sa Levijevim telima, i Parkinsonove bolesti.^[4] On deluje kao reversiblni inhibitor acetilholinesteraze i butirilholinesteraze, i kao ireverzibilni inhibitor monoamiske oksidaze B. On kombinuje mehanizme dejstva starijih lekova kao što su rivastigmin i rasagilin u jedan molekul.^[5]^[6] Osim neuroprotektivnih svojstava, ladostigil poboljšava izražavanje neurotrofnih faktora poput GDNF i BDNF, a moguće je da ima sposobnost povraćanja dela oštećenja prisutnih kod neurodegenerativnih bolesti putem indukcije neutrogeneze.^[7] Ladostigil takođe ima antidepresivno dejstvo, i može da bude koristan pri lečenju depresije i anksioznosti.^[8]^[9]

Reference[uredi - уреди | uredi izvor]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3. edit
↑ Weinstock M, Bejar C, Wang RH, et al. (2000). „TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease”. Journal of Neural Transmission. Supplementum (60): 157–69. PMID 11205137.
↑ Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). „Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 163–74. DOI:10.1016/j.nurt.2008.10.030. PMID 19110207. http://linkinghub.elsevier.com/retrieve/pii/S1933-7213(08)00226-2.
↑ Weinstock M, Luques L, Bejar C, Shoham S (2006). „Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression”. Journal of Neural Transmission. Supplementum (70): 443–6. PMID 17017566.
↑ Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). „Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy”. Annals of the New York Academy of Sciences 1122: 155–68. DOI:10.1196/annals.1403.011. PMID 18077571. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2007&volume=1122&spage=155.
↑ Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). „Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression”. Psychopharmacology 160 (3): 318–24. DOI:10.1007/s00213-001-0978-x. PMID 11889501.
↑ Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). „A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease”. Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (4): 555–61. DOI:10.1016/S0278-5846(03)00053-8. PMID 12787840. http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(03)00053-8.

Vidi još[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3. edit

[pmid11205137-4] Weinstock M, Bejar C, Wang RH, et al. (2000). „TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease”. Journal of Neural Transmission. Supplementum (60): 157–69. PMID 11205137.

[pmid19110207-5] Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). „Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 163–74. DOI:10.1016/j.nurt.2008.10.030. PMID 19110207. http://linkinghub.elsevier.com/retrieve/pii/S1933-7213(08)00226-2.

[pmid17017566-6] Weinstock M, Luques L, Bejar C, Shoham S (2006). „Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression”. Journal of Neural Transmission. Supplementum (70): 443–6. PMID 17017566.

[pmid18077571-7] Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). „Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy”. Annals of the New York Academy of Sciences 1122: 155–68. DOI:10.1196/annals.1403.011. PMID 18077571. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2007&volume=1122&spage=155.

[pmid11889501-8] Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). „Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression”. Psychopharmacology 160 (3): 318–24. DOI:10.1007/s00213-001-0978-x. PMID 11889501.

[pmid12787840-9] Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). „A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease”. Progress in Neuro-psychopharmacology & Biological Psychiatry 27 (4): 555–61. DOI:10.1016/S0278-5846(03)00053-8. PMID 12787840. http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(03)00053-8.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

Ladostigil

Reference[uredi - уреди | uredi izvor]

Vidi još[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Navigacijski meni

Traži-Тражи